Sucampo Pharma, Ltd., Announces Start Of Phase 2b Study In Japan To Evaluate Lubiprostone For Chronic Idiopathic Constipation
Sucampo Pharma Ltd. (SPL), a wholly-owned Japanese subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a specialty pharmaceutical company developing prostone-based therapies for age-related and other diseases, announced the initiation of a multi-center Phase 2b dose-ranging study in Japan to evaluate the safety and efficacy of lubiprostone for adult Chronic Idiopathic Constipation. [click link for full article]
More: continued here